Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30991815 | 1.00 | MTNR1A (0.42) | MTNR1AMTNR1BDRD2MCL1CA1 | |
| SCHEMBL29208507 | 0.84 | NAMPT (0.37) | DRD2CA1CA2HDAC8 | |
| SCHEMBL29208505 | 0.84 | EP300 (0.42) | CA1CA2HDAC6HDAC1HDAC8 | |
| SCHEMBL29208400 | 0.83 | HDAC8 (0.47) | CA1CA2HDAC6HDAC1HDAC8 | |
| SCHEMBL24414605 | 0.82 | KDM4E (0.47) | MTNR1AMTNR1BMCL1HDAC6HDAC1 | |
| SCHEMBL29208492 | 0.79 | BRD9 (0.44) | HDAC6HDAC1HDAC8 | |
| SCHEMBL29588065 | 0.79 | BRD9 (0.44) | HDAC6HDAC1HDAC8 | |
| SCHEMBL17997425 | 0.78 | MTNR1A (0.60) | MTNR1AMTNR1BHDAC6HDAC1HDAC8 | |
| SCHEMBL7672969 | 0.77 | MTNR1A (0.51) | MTNR1AMTNR1B | |
| SCHEMBL7671707 | 0.77 | KMO (0.54) | MTNR1AMTNR1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-3931188-B1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| CN-113474340-A | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors | 勃林格殷格翰国际有限公司 | 2021-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | NRAS, KRAS, RASSF5 | MTNR1A 1048/4885MTNR1B 1440/4885DRD2 1253/4885 |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | NRAS, RASSF5, KRAS | MTNR1A 1100/4885MTNR1B 1459/4885DRD2 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.